Evidence map›Paper›PMID 20038637›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

Development of promyelocytic zinc finger and ThPOK-expressing innate gamma delta T cells is controlled by strength of TCR signaling and Id3.

Eric S Alonzo, Rachel A Gottschalk, Joy Das, Takeshi Egawa, Robin M Hobbs, Pier Paolo Pandolfi, Pablo Pereira, Kim E Nichols, Gary A Koretzky, Martha S Jordan and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 153 citations in OpenAlex.

  1. Article
  2. HEB collaborates with TCR signaling to upregulatebioRxiv : the preprint server for biology · 2025
    Article
  3. Review
  4. Regulation of HSC development and function by Lin28b.Frontiers in cell and developmental biology · 2025
    Review
  5. T Cell Development: From T-Lineage Specification to Intrathymic Maturation.Advances in experimental medicine and biology · 2025
    Review
  6. Transcriptional network dynamics in early T cell development.The Journal of experimental medicine · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Development of γδ T Cells: Soldiers on the Front Lines of Immune Battles.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Eric S AlonzoImmunology Program, Sloan-Kettering Institute, New York, NY, 10065, USA.
Rachel A Gottschalk
Joy Das
Takeshi Egawa
Robin M Hobbs
Pier Paolo Pandolfi
Pablo Pereira
Kim E Nichols
Gary A Koretzky
Martha S Jordan
Derek B Sant'Angelo
Beth Israel Deaconess Medical Center · USCancer Research Institute · USMemorial Sloan Kettering Cancer Center · USChildren's Hospital of Philadelphia · USCornell University · USInserm · FRKettering University · USNew York University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Immunobiology of NKT cell development and functionR01AI059739 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI SANT'ANGELO, DEREK B. · 2006 to 2010
$2.5M
The function of PLZF in innate T cellsR01AI083988 · NIAID · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI SANT'ANGELO, DEREK B. · 2010 to 2014
$2.2M
Translational linkage strategies for DNA vaccines against cancerF31CA130744 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALONZO, ERIC SCOTT · 2007 to 2010
$165k
NCI NIH HHS F31 CA130744NCI NIH HHS F31CA130744NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA 08748NIAID NIH HHS AI059739NIAID NIH HHS R01 AI059739NIAID NIH HHS R01 AI083988
6 · The paper itself

Abstract

The broad-complex tramtrack and bric a brac-zinc finger transcriptional regulator (BTB-ZF), promyelocytic leukemia zinc finger (PLZF), was recently shown to control the development of the characteristic innate T cell phenotype and effector functions of NK T cells. Interestingly, the ectopic expression of PLZF was shown to push conventional T cells into an activated state that seems to be proinflammatory. The factors that control the normal expression of PLZF in lymphocytes are unknown. In this study, we show that PLZF expression is not restricted to NK T cells but is also expressed by a subset of gammadelta T cells, functionally defining distinct subsets of this innate T cell population. A second BTB-ZF gene, ThPOK, is important for the phenotype of the PLZF-expressing gammadelta T cells. Most importantly, TCR signal strength and expression of inhibitor of differentiation gene 3 control the frequency of PLZF-expressing gammadelta T cells. This study defines the factors that control the propensity of the immune system to produce potentially disease-causing T cell subsets.

Indexed as

Immunity, InnateAnimalsCell DifferentiationCell LineageImmunophenotypingInhibitor of Differentiation ProteinsKruppel-Like Transcription FactorsLymphocyte CountMiceMice, Inbred C57BLMice, KnockoutMyeloid Progenitor CellsPromyelocytic Leukemia Zinc Finger ProteinReceptors, Antigen, T-Cell, gamma-deltaSignal TransductionT-Lymphocyte SubsetsIdb3 protein, mouseInhibitor of Differentiation ProteinsKruppel-Like Transcription FactorsPromyelocytic Leukemia Zinc Finger ProteinReceptors, Antigen, T-Cell, gamma-deltaTranscription FactorsZbtb16 protein, mouseZbtb7b protein, mouse

Identifiers

PMID20038637
PMCPMC3991695
OpenAlexW1863038493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.